Once valued at $9B, Theranos to close

Amy Baxter | | Health Exec | Precision Medicine
6638074343_dab655b246_b.jpg

Theranos, the Silicon Valley-based blood-testing startup that was once valued at $9 billion, is dissolving. The company has been clad in scandal after reports revealed Theranos’ trademark service­–to test blood with a single pinprick–wasn’t effective or accurate.

Its founder, Elizabeth Holmes, once heralded as the next Steve Jobs by Inc. Magazine, and Sunny Balwani, Theranos’s former president and COO, are facing criminal charges for defrauding investors out of hundreds of millions of dollars.

The Washington Post first reported the story on the company’s closure, which was detailed in a note to shareholders issued Monday by CEO and General Counsel David Taylor. Theranos will pay its creditors after turning over its assets and intellectual property to Fortress, a credit and investment firm.

The move will leave Theranos with $5 million to pay creditors. It owes more than $60 million.

Read the full story below:

Blood-testing company Theranos will dissolve, pay creditors

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Biden chooses semaglutide for next round of Medicare price negotiations—Trump gets final say

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

AI in Healthcare
4 ways HHS plans to help shape a national strategy for healthcare AI

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.

Cardiovascular Business
FDA announces recall after Philips heart monitor software failed to send alerts—multiple deaths reported

Philips is recalling the software associated with its Mobile Cardiac Outpatient Telemetry devices after certain high-risk ECG events were never routed to trained cardiology technicians as intended. The issue, which lasted for two years, has been linked to more than 100 injuries.